Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $44 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
Tweet
Share
E-mailGet Alerts ARQT Hot Sheet
Price: $32.00 --0%
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 17 | New: 12
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $44.00 (from $38.00) while maintaining a Buy rating.
You May Also Be Interested In
- JPMorgan Downgrades LG Energy Solution (373220:KS) to Neutral
- Luxshare Precision (002475:CH) PT Lowered to RMB88 at JPMorgan
- Kakaopay (377300:CH) PT Lowered to KRW23,000 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
